The May issue of The American Journal of Psychiatry includes editorials critical of standard research design for drug studies and those undertaken with insufficient attention to racial differences.
“What is the meaning of the incremental cost of an active treatment compared with placebo when substantial costs attributed to the placebo exist only because of the research design?” asks one editorial, commenting on a drug study treating adolescents and depression.
Another editorial laments that "'monocultural ethnocentrism" continues to pervade "good science" in psychiatric research to the detriment of African-Americans."
